Cost effectiveness of pembrolizumab for unresectable metastatic melanoma after progression with ipilimumab in England.

Authors:

Marriott E-R, Praet C, Aguiar-Ibanez R, Pellissier J, Xu R and Wang J.

Publication Type:

Conference Proceedings – Poster

Publication Name:

18th International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual European Congress

Citation:

Marriott E-R, Praet C, Aguiar-Ibanez R, Pellissier J, Xu R and Wang J. Cost effectiveness of pembrolizumab for unresectable metastatic melanoma after progression with ipilimumab in England. 18th International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual European Congress. Milan, Italy. 7-11 November 2015. Poster PCN134.


Link to publication ⟶

⟵ Back to Search Results

By continuing to browse or by clicking "Accept All Cookies" you agree to the storing of first and third-party cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
Cookie Policy
Accept All Cookies
By continuing to browse or by clicking "Accept All Cookies" you agree to the storing of first and third-party cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
Cookie Policy
Accept All Cookies